Moreover, elevated levels of CCNB1 and PLK-1 are known to be strongly associated with low overall survival in other solid tumors like breast cancer, demonstrating their potentiality as prognostic markers and as combinatorial drug targets [53]. Here, CCNB1 is linked to breast cancer.